Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver

[Guest guest]

http://www.cghjournal.org/article/PIIS1542356510008955/abstract?rss=yes

Clinical Gastroenterology and Hepatology

Volume 8, Issue 12 , Pages 1017-1029, December 2010

son IM et al.

Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver

In addition to its effects in the liver, chronic hepatitis C virus (HCV)

infection can have serious consequences for other organ systems. Extrahepatic

manifestations include mixed cryoglobulinemia (MC) vasculitis,

lymphoproliferative disorders, renal disease, insulin resistance, type 2

diabetes, sicca syndrome, rheumatoid arthritis–like polyarthritis, and

autoantibody production; reductions in quality of life involve fatigue,

depression, and cognitive impairment. MC vasculitis, certain types of lymphoma,

insulin resistance, and cognitive function appear to respond to anti-HCV

therapy. However, treatments for HCV and other biopsychosocial factors can

reduce quality of life and complicate management. HCV treatment has a high

overall cost that increases when extrahepatic manifestations are considered. HCV

appears to have a role in the pathogenesis of MC vasculitis, certain types of

lymphoma, and insulin resistance. Clinicians who treat patients with HCV

infections should be aware of potential extrahepatic manifestations and how

these can impact and alter management of their patients.

[Guest guest]

http://www.cghjournal.org/article/PIIS1542356510008955/abstract?rss=yes

Clinical Gastroenterology and Hepatology

Volume 8, Issue 12 , Pages 1017-1029, December 2010

son IM et al.

Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver

In addition to its effects in the liver, chronic hepatitis C virus (HCV)

infection can have serious consequences for other organ systems. Extrahepatic

manifestations include mixed cryoglobulinemia (MC) vasculitis,

lymphoproliferative disorders, renal disease, insulin resistance, type 2

diabetes, sicca syndrome, rheumatoid arthritis–like polyarthritis, and

autoantibody production; reductions in quality of life involve fatigue,

depression, and cognitive impairment. MC vasculitis, certain types of lymphoma,

insulin resistance, and cognitive function appear to respond to anti-HCV

therapy. However, treatments for HCV and other biopsychosocial factors can

reduce quality of life and complicate management. HCV treatment has a high

overall cost that increases when extrahepatic manifestations are considered. HCV

appears to have a role in the pathogenesis of MC vasculitis, certain types of

lymphoma, and insulin resistance. Clinicians who treat patients with HCV

infections should be aware of potential extrahepatic manifestations and how

these can impact and alter management of their patients.